ASO Author Reflections: Multimodality Treatment in Anaplastic Thyroid Cancer: Improving Survival Outcomes and Balancing Treatment Related Complications

Pascal K C Jonker^{1

2}, Mark Sywak^{3

4}

Affiliations

¹ University of Sydney Endocrine Surgical Unit, Royal North Shore Hospital, Northern Sydney Local Health District, St Leonards, NSW, Australia.
² Department of Surgery, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
³ University of Sydney Endocrine Surgical Unit, Royal North Shore Hospital, Northern Sydney Local Health District, St Leonards, NSW, Australia. marksywak@nebsc.com.au.
⁴ Northern Clinical School, Sydney Medical School, Faculty of Medicine and Health, University of Sydney, Sydney, NSW, Australia. marksywak@nebsc.com.au.

Comment

Pascal K C Jonker et al. Ann Surg Oncol. 2021 Nov.

. 2021 Nov;28(12):7531-7532.

doi: 10.1245/s10434-021-10268-8. Epub 2021 Jun 15.

Pascal K C Jonker^{1

2}, Mark Sywak^{3

4}

¹ University of Sydney Endocrine Surgical Unit, Royal North Shore Hospital, Northern Sydney Local Health District, St Leonards, NSW, Australia.
² Department of Surgery, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
³ University of Sydney Endocrine Surgical Unit, Royal North Shore Hospital, Northern Sydney Local Health District, St Leonards, NSW, Australia. marksywak@nebsc.com.au.
⁴ Northern Clinical School, Sydney Medical School, Faculty of Medicine and Health, University of Sydney, Sydney, NSW, Australia. marksywak@nebsc.com.au.

No abstract available

Comment on

Multimodality Treatment Improves Locoregional Control, Progression-Free and Overall Survival in Patients with Anaplastic Thyroid Cancer: A Retrospective Cohort Study Comparing Oncological Outcomes and Morbidity between Multimodality Treatment and Limited Treatment.
Jonker PKC, Turchini J, Kruijff S, Lin JF, Gill AJ, Eade T, Aniss A, Clifton-Bligh R, Learoyd D, Robinson B, Tsang V, Glover A, Sidhu S, Sywak M. Jonker PKC, et al. Ann Surg Oncol. 2021 Nov;28(12):7520-7530. doi: 10.1245/s10434-021-10146-3. Epub 2021 May 25. Ann Surg Oncol. 2021. PMID: 34032961

1. Molinaro E, Romei C, Biagini A, et al. Anaplastic thyroid carcinoma: from clinicopathology to genetics and advanced therapies. Nat Rev Endocrinol. 2017;13(11):644–60. https://doi.org/10.1038/nrendo.2017.76 . - DOI - PubMed
1. Jonker PKC, Turchini J, Gill AJ, et al. Multimodality treatment improves loco-regional control and overall survival in Anaplastic Thyroid Cancer. Ann Surg Oncol. 2021. https://doi.org/10.1245/s10434-021-10146-3 . - DOI - PubMed - PMC
1. Blay J-Y, Coindre J-M, Ducimetière F, Ray-Coquard I. The value of research collaborations and consortia in rare cancers. Lancet Oncol. 2016;17(2):e62–9. https://doi.org/10.1016/S1470-2045(15)00388-5 . - DOI - PubMed
1. Jonker PKC, van Dam GM, Oosting SF, Kruijff S, Fehrmann RSN. Identification of novel therapeutic targets in anaplastic thyroid carcinoma using functional genomic mRNA-profiling: Paving the way for new avenues? Surgery. 2017;161(1):202–11. https://doi.org/10.1016/j.surg.2016.06.064 . - DOI - PubMed